Clinical Trial Update: Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/Phase 2 study evaluating WGI-0301 in combination with Lenvatinib for advanced hepatocellular carcinoma, with the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• WGI-0301

Snippet

Sponsor: Zhejiang Haichang Biotech Co., Ltd. | Conditions: Advanced Hepatocellular Carcinoma (HCC) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING